HAIR DYE AS A COLORFUL TRIGGER FOR RELAPSE OF ANTI-GBM DISEASE

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
HAIR DYE AS A COLORFUL TRIGGER FOR RELAPSE OF ANTI-GBM DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Mahima
Dhingra
Mahima Dhingra mahimadhingra@me.com Max Hospital Saket Department of Nephrology New Delhi India *
S Sobiya kulmin2k2@gmail.com Max Hospital Saket Department of Nephrology New Delhi India -
Kulwant Singh kulmin2k2@gmail.com Max Hospital Saket Department of Nephrology New Delhi India -
Deepak Kumar Panigrahi kulmin2k2@gmail.com Max Hospital Saket Department of Nephrology New Delhi India -
Abhishek Singh kulmin2k2@gmail.com Max Hospital Saket Department of Nephrology New Delhi India -
Dinesh Khullar kulmin2k2@gmail.com Max Hospital Saket Department of Nephrology New Delhi India -
 
 
 
 
 
 
 
 
 

Anti-GBM (anti-glomerular basement membrane) disease is a rare, monophasic, but serious autoimmune disease involving small vessels of the kidneys and lungs. It typically presents with rapidly progressive glomerulonephritis with or without pulmonary hemorrhage. The mainstay of treatment is plasma exchange, prednisolone and cyclophosphamide. Relapse are infrequent, but may be triggered by certain environmental irritants like cigarette smoking, inhalation of solvents, hair dye or certain infections. We report a case of 43 years old male who was diagnosed anti GBM disease on kidney biopsy done for rapidly progressive renal failure. He was treated with plasmapheresis, steroids and cyclophosphamide. After two months he re-presented with diffuse alveolar hemorrhage and raised anti GBM antibodies titre which was presumed due to use of new hair dye. In view of ongoing infection and recent history of strong immunosuppressants, he was successfully treated with a non-standard regimen of plasmapheresis, intravenous immunoglobulins (IVIG) and rituximab. 

 

Even after 5 sessions of plasmapheresis, as anti GBM titer was still high (236 U/ml), he was administered two doses of rituximab (500mg each - 15 days apart). This resulted in rapid reduction of anti-GBM antibody titer to 88 U/ml with significant clinical improvement.

This case illustrates an unusual relapse of anti-GBM disease precipitated by hair dye exposure, successfully managed with a combination of plasmapheresis, IVIG, and rituximab. It underscores the need for vigilance regarding potential triggers of relapse. It also highlights rituximab, as a valuable therapeutic option in relapsing cases, where the standard cytotoxic therapy is contraindicated.

Kewords